EMA seeks to optimize use of accelerated assessment and conditional authorization pathways
This article was originally published in SRA
The European Medicines Agency has proposed improvements relating to the use of its accelerated assessment and conditional marketing authorization pathways. Both pathways are designed to bring medicines that address unmet medical needs to market faster but have been criticized for failing to fully meet their intended aims1-4.
Register for our free email digests: